Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Japanese cedar pollen refers to the allergenic pollen grains produced by the Japanese cedar tree Cryptomeria japonica, which are a major cause of seasonal allergic rhinitis (“Japanese cedar pollinosis”) in Japan and other regions where the tree is cultivated. Extracts of Japanese cedar pollen, standardized by content of major allergens such as Cry j 1 and Cry j 2, are used as active pharmaceutical ingredients in allergen‑specific immunotherapy, particularly sublingual immunotherapy tablets that expose the oral mucosa to controlled doses of allergen over time to induce immune tolerance, shift T‑cell responses away from pathogenic Th2/Tpath2 cells, and expand regulatory T cells, thereby reducing IgE‑mediated hypersensitivity and alleviating nasal and ocular symptoms during pollen seasons.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on japanese cedar pollen.